Clinical Trial

OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
BS008-001 is a multicenter, open-label phase Ib /II trial in heavily pre-treated patients with advanced solid tumors. Patients received biweekly sequential intratumoral injections of OH2 (fixed dose: 10⁷ CCID₅₀/mL) followed by BS006 (dose escalation: 10⁶-10⁷ CCID₅₀/mL), with identical volumes being injected at the same lesion. The primary endpoint is safety and tolerability; secondary endpoints included efficacy outcomes assessed by RECIST 1.1/iRECIST.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-27.
Trial Details
NCT Number NCT07382531
Lead Sponsor Binhui Biopharmaceutical Co., Ltd.
Conditions Solid Tumor
Enrollment 30 participants
Start Date 2023-09-07
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-04